Full Press Release Details
Celcuity Presents Results at the 2019 San Antonio Breast Cancer
Symposium Evaluating a Sub-Group of PIK3CA WT Breast Cancer
Patients Who Have Hyperactive Signaling Tumors Responsive to PI3K
Minneapolis, Minnesota December 11, 2019 - Celcuity Inc.
(Nasdaq: CELC), a dynamic cellular analysis company developing
diagnostic tests to identify new patient populations for targeted
therapies, announced that it presented results from a study of its
newly developed CELx PI3K Signaling Function Test at the 2019 San
Antonio Breast Cancer Symposium on December 11, 2019.
The CELx PI3K Test identifies HER2-negative breast cancer patients
with hyperactive PI3K-involved signaling tumors that respond
to PI3K inhibitors. Currently, only
breast cancer patients with PIK3CA-mutations are eligible to
receive treatment with PI3K inhibitors. However, response rates of
20% or less to PIK3 drugs in recent Phase III clinical trials
suggest the need to measure other biological factors, such as
PIK3-involved signaling, when identifying patients eligible for
The studies we presented demonstrate how the measurement of
PI3K-involved signaling initiated by G-protein-couple receptors
(GPCRs) may provide a more sensitive and specific method of
identifying patients most likely to benefit from PI3K inhibitors
than PIK3CA-status, said Brian Sullivan, Chairman and Chief
Executive Officer of Celcuity.
Abstract #2224, Poster # P1-09-07
Title: Sub-Group of PIK3CA WT breast cancer patients have
hyperactive S1P and LPA signaling tumors responsive to PI3K
inhibitors: functional signaling test identifies new patient group
who may benefit from PI3K inhibitors
primary patient breast tumor cells and well characterized breast
cancer cell lines, this study set out to:
the involvement of the PI3K node in hyperactive S1P and
LPA-initiated signaling.
whether PI3K-involved hyperactive S1P and LPA signaling is limited
to breast cancer cells with PI3KCA mutations.
that two of three cell lines with PI3KCA-mutations lacked abnormal
PI3K-alpha isoform involved signaling.
a weak correlation between the status of PI3K-involved signaling
and PI3KCA gene mutation status.
that CELx PI3K Test results correlate with xenograft drug study
results using two different cell lines with
Abnormal pan-PI3K signaling corresponded with
significant in vivo anti-tumor effect of a pan-PI3K
Normal PI3K-alpha isoform signaling corresponded
vivo anti-tumor effect of a
PI3K-alpha isoform inhibitor.
that 4 of 17 (24%) patient tumor cell samples recorded total levels
of signaling activity involving PI3K isoforms initiated by S1P
activation above the test cut-off.
that abnormal S1P or LPA activity involving PI3K can occur in
PIK3CA WT patient primary cells.
Celcuity is a dynamic cellular analysis company developing
diagnostic tests to identify new patient populations for targeted
therapies. Celcuity's proprietary CELx diagnostic platform
uses a patient's living tumor cells to identify the specific
abnormal cellular activity driving a patient's cancer and the
targeted therapy that can best treat that patient's disease.
Celcuity is headquartered in Minneapolis, Minnesota. Further
information about Celcuity can be found at www.celcuity.com.
Forward-Looking Statements
This press release contains statements that constitute
forward-looking statements, including the anticipated
benefits to the clinical outcomes of cancer patients.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of Celcuity, which include, but are
not limited to, those set forth in the Risk Factors section of
Celcuity's Annual Report on Form 10-K for the year ended
December 31, 2018. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. Celcuity undertakes no obligation to update
these statements for revisions or changes after the date of this
release, except as required by law.
Sullivan, bsullivan@celcuity.com
Hahne, vhahne@celcuity.com